In renal failure, the use of recombinant human EPO is indicated to correct anemia.[4] In HF patients however, a large trial conducted recently was not able to show beneficial effects on clinical outcome.[5] Administration of recombinant human EPO might even be hazardous in these patients as it increased the risk of thromboembolic events.[5]. This evidence concerns the gene EPO and Renal insufficiency.